SPDR S&P Pharmaceuticals ETF
Price through Oct 6, 2026 · Flows through Oct 5, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Oct 6, 2026. Holdings snapshot retrieved Oct 6, 2026.
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 1Y SHOWN · NET +$254M OVER THIS RANGE
Money is leaving — −$69M in net outflows over the past month, about 14.2% of the fund's asset base, while the price has returned +12.3% so far this year. At 0.35% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | AMLXAMYLYX PHARMACEUTICALS | 2.04% | $28.04 | +0.9% | ||
| 2 | MBXMBX Biosciences | 2.72% | $56.92 | -2.8% | ||
| 3 | OMEROMEROS | 1.42% | $18.51 | -2.1% | ||
| 4 | DFTXDefinium Therapeutics | 3.09% | $35.62 | -1.7% | ||
| 5 | CORTCORCEPT THERAPEUTICS | 1.70% | $119.57 | -2.0% | ||
| 6 | AMRXAMNEAL PHARMACEUTICALS | 1.72% | $20.30 | -0.3% | ||
| 7 | ETONETON PHARMACEUTICALS | 1.30% | $54.77 | -1.5% | ||
| 8 | PRGOPERRIGO CO | 1.42% | $14.00 | -3.0% | ||
| 9 | EWTXEDGEWISE THERAPEUTICS | 1.88% | $40.02 | -0.7% | ||
| 10 | TARSTARSUS PHARMACEUTICALS | 1.57% | $74.11 | -0.5% | ||
| 11 | LGNDLIGAND PHARMACEUTICALS | 1.94% | $296.94 | -3.2% | ||
| 12 | MRKMERCK & CO | 1.65% | $141.94 | +1.7% | ||
| 13 | MANEVERADERMICS INC | 2.02% | $108.96 | -8.3% | ||
| 14 | XERSXERIS BIOPHARMA HOLDINGS | 1.39% | $10.07 | -0.6% | ||
| 15 | ELVNENLIVEN THERAPEUTICS | 2.09% | $42.39 | -6.8% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 41| 1 week | -3.2% |
| 1 month | -11.3% |
| 3 months | -6.5% |
| 6 months | +15.0% |
| YTD | +12.3% |
| 1 year | +29.4% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | −$32M |
| 1 month | −$69M |
| 3 months | +$83M |
| YTD | +$226M |
| 1 year | +$254M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 3.1% of the book; the top ten carry 22%. Spread across 66+ names, it behaves like roughly 60 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| LLY ELI LILLY | $48M | $46M |
| JNJ JOHNSON & JOHNSON | $3M | $4M |
| BMY BRISTOL MYERS SQUIBB | $1M | $5M |
| MRK MERCK & CO | $3M | $2M |
| CORT CORCEPT THERAPEUTICS | $3M | $776,454 |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat XPH on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41B | +$286M | -32bp on fee · 84× the assets · +$286M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -32bp on fee · 38× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.4B | +$497M | -31bp on fee · 67× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.3B | +$575M | -31bp on fee · 48× the assets · +$575M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -31bp on fee · 38× the assets · +$412M in over the month | Head-to-head |